An opinion piece in The Atlantic about the $3 billion settlement against GlaxoSmithKline makes the point that even a relatively large financial penalty is unlikely to stop a company that still makes a profit from illegal activities. The solution, The Atlantic says, is to change a system that essentially allows companies to monitor themselves.
The British drugmaker’s agreement with the U.S. Justice Department to pay $3 billion in criminal and civil ...
continue reading...
Dr. Drew Pinsky – well-known as TV and radio host “Dr. Drew” – is dealing with criticism after court records revealed that he took $275,000 from GlaxoSmithKline for “services for Wellbutrin.”
GlaxoSmithKline recently agreed to a $3 billion settlement — the largest ever involving a pharmaceutical company – over the federal government’s charges that the company illegally marketed some of its medications.
Prosecutors allege that the British pharmaceutical giant’s tactics included paying ...
continue reading...The $3 billion fine recently leveled against GlaxoSmithKline is the largest settlement ever involving a pharmaceutical company. But in light of the enormous profits that the British pharmaceutical giant brings in, some critics wonder whether even that will be enough to dissuade companies from engaging in dangerous fraud.
GlaxoSmithKline pleaded guilty to marketing drugs for unapproved uses, according to a New York Times report. Among the charges is that the company ...
continue reading...
In a piece for the Wall Street Journal, writer Katherine Sharpe argues that antidepressants are overprescribed in the United States, and discusses the challenges that face a growing segment of population – young people who have no conception of who they are when they aren’t on antidepressants.
She cites figures from the National Center for Health Statistics, which state that 5 percent of American 12- to 19-year-olds use antidepressants, and another ...
continue reading...GlaxoSmithKline has agreed to pay $3 billion in fines for fraudulently promoting medications for unapproved uses. According to a New York Times report, it’s the largest settlement ever leveled against a pharmaceutical company.
But the settlement doesn’t end the company’s legal disputes. Widespread lawsuits allege that GlaxoSmithKline and other manufacturers of antidepressants classified as selective serotonin reuptake inhibitors failed to adequately warn pregnant patients of studies linking the drugs to continue reading...
U.S. Senator Charles Schumer of New York is calling for a nationwide effort to combat the problem of babies born addicted to prescription painkillers or other opiates, known as Neonatal Abstinence Syndrome (NAS).
In a news release on the issue, Schumer cites a study published in the Journal of the American Medical Association (JAMA), which found that approximately 3.4 of every 1,000 infants born in 2009 suffered from NAS. That amounts ...
continue reading...
